Home › Funds › ORBIMED ADVISORS LLC › XENE

ORBIMED ADVISORS LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

ORBIMED ADVISORS LLC reported holding 892,471 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$53.9M, representing 1.08% of its reported portfolio and ranking #27 among its reported holdings. ORBIMED ADVISORS LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)892.47K sh
Reported value held$53.87M
Portfolio Weight1.08%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's XENE position evolved

ORBIMED ADVISORS LLC first disclosed a stake in XENE in Q3 2023 at 958,793 shares (US$32.8M). The position peaked in Q1 2026 at 1,059,971 shares, worth US$61.6M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 892,471 shares valued at US$53.9M — a reduction of -167,500 shares quarter over quarter.. Notable position changes include a 57% increase in Q2 2024 (shares were roughly flat over the following quarter), a 56% trim in Q3 2025 (shares rose 12% over the following quarter), a 137% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 958.79K $32.75M New
Q4 2023 550.00K $25.33M Reduce
Q1 2024 550.00K $23.68M Hold
Q2 2024 862.36K $33.62M Add
Q3 2024 911.42K $35.88M Add
Q4 2024 947.88K $37.16M Add
Q1 2025 947.88K $31.80M Hold
Q2 2025 947.88K $29.67M Hold
Q3 2025 419.60K $16.85M Reduce
Q4 2025 447.20K $20.04M Add
Q1 2026 1.06M $61.64M Add
Q2 2026 892.47K $53.87M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held XENE?

ORBIMED ADVISORS LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in XENE?

As of Q2 2026, ORBIMED ADVISORS LLC holds 892.47K shares of XENE (XENON PHARMACEUTICALS INC), valued at $53.87M, representing 1.08% of its reported portfolio and ranking #27.

Has ORBIMED ADVISORS LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC reduced its position in XENE. The position peaked in Q1 2026 at 1.06M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.